AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S. PRESS RELEASE PR Newswire . Feb. 28, 2022, 04:15 PM.

NORTH CHICAGO, Ill., Sept. 12, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI ®, 600 mg ...

AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation.

AbbVie Inc. ABBV announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for Skyrizi (risankizumab), for a new indication ...

AbbVie won approval for Skyrizi in Crohn’s disease, an adjacent indication to ulcerative colitis, in 2022 and has heavily promoted the drug. Skyrizi is a recurring name at the top of the list of ...

AbbVie ABBV announced that its key drug, Skyrizi (risankizumab) met all primary and secondary endpoints of a head-to-head phase III study comparing the drug against J&J’s JNJ blockbuster ...

Skyrizi plus arthritis and atopic dermatitis med Rinvoq are the linchpins in AbbVie’s post-Humira strategy. The company recently reconfirmed its projection that the meds would clinch a combined ...

That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a disease that impacts around 1.5 million Americans.

Improved sales expectations for Skyrizi and Rinvoq and acquisitions in oncology and neuroscience add confidence AbbVie can continue growing. I now see EPS growing at 8.2% per year through 2030 ...

AbbVie, Inc. ABBV announced that it submitted a regulatory application with the European Medicines Agency (EMA), seeking approval for its interleukin-23 (“IL-23”) inhibitor risankizumab ...